Every year, more than 6 million people are diagnosed with and more than 4 million people die from cancer all over the world, which is approximately 10% of the total mortality. The incidence of cancer in Ukraine shows a gradual increase, with the number of newly diagnosed patients 304-308 per 100 thousand people. Bladder cancer ranks second in the world among oncological diseases of the urinary system after prostate cancer. In the later stages of diseases, their course may be associated with malignant neoplasm anemia. The purpose of the study was to study the content of 2,3-diphosphoglycerate in erythrocytes of peripheral venous blood of patients with malignant neoplasm anemia with urothelial bladder cancer and prostate cancer, depending on the severity of anemia; to evaluate the possible diagnostic and prognostic value of the studied indicator. Materials and methods. 96 patients (64 men and 32 women) with urothelial bladder cancer were examined. There were 39 patients (28 men and 11 women) among them, the course of their underlying disease was not accompanied by the presence of anemia (first (I) observation group) and 57 patients (36 men and 21 women), the course of their underlying disease was aggravated by malignant neoplasm anemia (second (II) observation group). Also, 48 men with prostate cancer whose course of the disease was not aggravated by malignant neoplasm anemia (19 men) (third (III) observation group) and 29 men (fourth (IV) observation group) were diagnosed with malignant neoplasm anemia. The age of the patients under the survey was from 22 to 79 years old. All patients were examined after verifying the diagnosis and before starting any treatment. The content of 2,3-diphosphoglycerate in erythrocytes of peripheral venous blood was determined by the method of I. S. Luganova, M. N. Blinov (1975). Results and discussion. The content of 2,3-diphosphoglycerate in peripheral venous erythrocytes of patients with malignant neoplasm anemia due to urothelial bladder cancer and prostate cancer has been studied. It was found that malignant neoplasm anemia in patients with urothelial bladder cancer and prostate cancer is associated with an increase in the studied indicator (p<0.05). The article discusses the possible causes and pathogenetic mechanisms of the identified changes. Conclusion. Patients with urothelial bladder cancer and prostate cancer have an imbalance of energy metabolism that occurs in erythrocytes. This process is manifested by an increase in the amount of 2,3-diphosphoglycerate

Keywords: /archive?abs=on&q=, 3-diphosphoglycerate, erythrocytes, malignant neoplasm anemia, cancer, bladder, prostate gland

Full text: PDF (Rus) 265K

1. American Cancer Society: Cancer Facts and Figures 2010. Atlanta, GA: American Cancer Society; 2010. p. 66-71.
2. Didyk IV. Rak peredmichurovoi zalozy jak svitova problema. Poshyrenist’ factory rysyku, svoechasnist’ diagnostuky (оgliad literatury) [Prostate cancer as a global problem. Prevalence, risk factors, diagnosis, the timelines of diagnosis (review)]. Ukr. Med Tsasopys. Ukr Med J. 2016; 3(113): 62-64. [Ukrainian]
3. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012; 30(2): 196-200. https://www.ncbi.nlm.nih.gov/pubmed/22476558. https://doi.org/10.1007/s00345-012-0824-2
4. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012; 45: 152-156. https://www.ncbi.nlm.nih.gov/pubmed/23271766. https://www.ncbi.nlm.nih.gov/pmc/articles/3540881. https://doi.org/10.1093/jncimonographs/lgs035
5. Saidakova NO, Yatsyna OI, Stus VP, Polion MY, Kononova GE, Shilo VM. Dynamics of mortality of different laers in the population of Ukraine due to urinary bladder cancer in the regional aspect. Urologiya. 2021; 25(1): 5-10. https://doi.org/10.26641/2307-5279.25.2.2021.238234
6. Moch H, Humphrey PA, Ulbright TM, Reuter V. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs. Lyon, France; International Agency for Research of Cancer. Eur Urology. 2016; 70: 101–119. https://www.ncbi.nlm.nih.gov/pubmed/26996659. https://doi.org/10.1016/j.eururo.2016.02.028
7. Titov EV. Sovremennye metody diagnostiki i prognoza urotelial’nych rakov mochevogo pusyrja [Modern methods of diagnostics and prediction of urothelial cancer of the urinary bladder]. Problemy bezperervnoi medychnoi osvity ta nauky. 2018; 2(29): 86-91. [Russian]. https://doi.org/10.31071/promedosvity2018.02.086
8. Vydyborets S, Andriiaka A. Sovremennye prinzypy lechenija anemii u pazientov c onkogematologicheskimi i onkologicheskimi zabolevanijami [Modern strategy to treatment of anemia in patients with hematologic and solid tumors]. Hematologija. Transfusiologija. Vostochnaja Evropa. 2016; 2(3): 388-396. [Russian]
9. Berganaschi G, Di Sabatino A, Pasini A. Intestinal expression of genes implicated in iron absorption and their regulation by hepcidin. Clin Nutrition. 2017; 36: 1427-1433. HTTPS://WWW.NCBI.NLM.NIH.GOV/PUBMED/27729173. https://doi.org/10.1016/j.clnu.2016.09.021
10. Luniova GG, Ed. Klinichna biochimiia [Clinical Biochemistry]: Handbook. K: Atika; 2013. 1156 p. [Ukrainian]
11. Savlukov AI, Kamilov RF, Samsonov VM, Shakirov DF. Energeticheskoe sostoyanie erytrozytov pri vozdejstvij chimicheskih zagrjaznitelej [The energy status of red blood cells upon exposure to chemical pollutants]. Klin Lab Diagnostika. 2011; 2: 26-29. [Russian]
12. Titovets E, Novikova I. Novye predstavleniya o gasotransportnoj funkzii erytrocytov [New views on the erytrocyte gas transfer function]. Lab Diagnostika. Vostochnaja Evropa. 2014; 3(11): 31-39. [Russian]
13. Derpak YY. Dinamika pokazatelej soderzhaniya 2,3-diphospoglicerata v erytrocytah reguliarnyh donorov krovi v processe korekzii latentnogo deficita zheleza [Dynamics of 2,3-diphospoglicerate existence indicators in erythrocytes of regular blood donors during the process of latent iron deficiency]. Hematologija. Transfusiologija. Vostochnaja Evropa. 2015; 2(2): 54-59. [Russian]
14. Luganova IS, Blinov MN. Opredelenie 2,3-diphosphoglycerinovoj kisloty neenzimaticheskim metodom i soderzhaniya 2,3-diphosphoglycerata i ATF v erytrozytah bolnyh hronicheskim limpholeikozom [Determination of 2,3-diphosphoglycerinic acid with non-viimatic method and content of 2,3-diphosphoglycerat and ATP in erythroses of patients with chronic lympholoicosis]. Laboratornoe delo. 1975; 11: 652-654. [Russian]
15. Borysenko DA, Vydyborets SV. Diagnosticheskoe i prognosticheskoe znachenie soderzhaniya glukoso-6-phosphatdegidrogenasy v erytrocytah pazientov s anemiej zlokachetvennogo novoobrazovaniya pry urotelialnom rake mochevogo puzyrya [Diagnostic and prognostic value of the contents of glucose-6-phosphatdegidrogenase in erythrocytes of patients with anemia of malignant neoplasm in urothelial cancer of the urinary bladder]. Hematologija. Transfusiologija. Vostochnaja Evropa. 2020; 6(1): 24-34. [Russian]. https://doi.org/10.34883/PI.2020.6.1.002
16. Borysenko DA, Vydyborets SV. Soderzhanie glukosy v erytrocytah pazientov s anemiej zlokachetvennogo novoobrazovaniya pry urotelialnom rake mochevogo puzyrya [The contents of glucose in erythrocytes of patients with anemia of malignant neoplasm in urothelial cancer of the urinary bladder]. Hematologija. Transfusiologija. Vostochnaja Evropa. 2020; 6(3): 319-323. [Russian]. https://doi.org/10.34883/PI.2020.6.3.017